Drug Profile

HSK 31679

Alternative Names: HSK-31679

Latest Information Update: 27 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Haisco Pharmaceutical Group
Class Antihyperlipidaemics; Antithrombotics
Mechanism of Action Thyroid hormone receptor beta agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Non-alcoholic steatohepatitis
Phase II Hypercholesterolaemia

Most Recent Events

17 Jul 2026 Phase-III clinical trials in Non-alcoholic steatohepatitis (PO) prior to July 2026 (Haisco Pharmaceutical pipeline, July 2026)
12 May 2026 Haisco Pharmaceutical plans a phase-III trial for Non-alcoholic steatohepatitis in June 2026 (PO, tablet) (NCT07581951)
16 Jan 2026 Haisco Pharmaceutical completes a phase IIb trial in Non-alcoholic steatohepatitis in China (PO) (NCT06168383)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com